The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response

Rebekah L. I. Crake†, Eleanor R. Burgess†, Janice A. Royds², Elisabeth Phillips¹, Margreet C. M. Vissers³ and Gabi U. Dachs¹*

¹ Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand, ² Department of Pathology, University of Otago, Dunedin, New Zealand, ³ Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand

Gliomas are a heterogeneous group of cancers that predominantly arise from glial cells in the brain, but may also arise from neural stem cells, encompassing low-grade glioma and high-grade glioblastoma. Whereas better diagnosis and new treatments have improved patient survival for many cancers, glioblastomas remain challenging with a highly unfavorable prognosis. This review discusses a super-family of enzymes, the 2-oxoglutarate dependent dioxygenase enzymes (2-OGDD) that control numerous processes including epigenetic modifications and oxygen sensing, and considers their many roles in the pathology of gliomas. We specifically describe in more detail the DNA and histone demethylases, and the hypoxia-inducible factor hydroxylases in the context of glioma, and discuss the substrate and cofactor requirements of the 2-OGDD enzymes. Better understanding of how these enzymes contribute to gliomas could lead to the development of new treatment strategies.

Keywords: hypoxia, brain cancer, PHD, HIF-1, TET, IDH, ascorbate

INTRODUCTION

Gliomas and glioblastomas are brain cancers with significant morbidity and mortality, and limited treatment options. Our review will briefly describe these neoplasms, then concentrate on a super-family of enzymes, the 2-oxoglutarate dependent dioxygenase enzymes (2-OGDD), with dozens of members currently known (Figure 1). 2-OGDDs participate in numerous processes including collagen and hormone synthesis, fatty acid metabolism, stress signaling, epigenetic modifications and oxygen sensing (2–7). We will discuss specific members of the 2-OGDD family that have attracted recent interest, including the DNA demethylases [ten-eleven translocases (TET)], the histone demethylases [Jumonji-C domain-containing demethylases (JmjC)], and the hypoxia-inducible factor (HIF) hydroxylases. These enzymes require molecular oxygen and 2-oxoglutarate [2-OG, produced by isocitrate dehydrogenase (IDH)] as substrates, and non-ferrous iron (Fe²⁺) and
vitamin C (ascorbate) as cofactors. Decreased availability of either substrate or co-factors reduces 2-OGDD enzyme activity, resulting in these enzymes acting as cellular sensors of energy metabolism, oxygen availability, and iron homeostasis (2–4, 8–14). Finally, we consider the potential means of modifying the activity of the 2-OGDDs, specifically by modulating ascorbate availability.

GLIOMA AND GliOBlastoma AND TREATMENT OPTIONS

Gliomas are a heterogeneous group of neoplasms that arise from glial cells in the brain (15, 16), or neural stem cells (17). Low-grade gliomas, grades II and III, include astrocytomas and oligodendrogliomas which predominantly develop from astrocytes or oligodendrocytes, respectively. Glioblastomas (GBM) are grade IV and can develop either as a high-grade lesion (primary GBM), or from astrocytoma progression (secondary GBM) (15, 16).

Gliomas accounted for 1.6% of cancer diagnoses and 2.5% of cancer related deaths worldwide in 2018 (18). Astrocytomas, oligodendrogliomas and secondary GBM tend to develop in younger individuals (median age 35, 45, and 38 years, respectively), compared to primary GBM (median age of 55 years) (17, 19). Gliomas are identified by magnetic resonance imaging (MRI) or computed tomography (CT/CAT). Although treatment options are available as detailed below, high grade gliomas are incurable (20–23). Some low grade gliomas can be cured, although these are rare (17). Following diagnosis, the median survival for patients with oligodendroglialoma can be up to 16 years, for astrocytoma 5–8 years, and for GBM only 15–31 months (17, 24).

The current standard treatment for gliomas focuses on extending patient survival and includes maximal safe debulking surgery followed by radiotherapy and concomitant or adjuvant chemotherapy (20), usually with the alkylating agent temozolomide (20, 21, 25, 26). Debulking surgery is performed to reduce intracranial pressure and neurological symptoms, while resected tissue is utilized for tumor classification (17, 22, 23). Post-treatment recurrence is common with approximately 80% of gliomas recurring in close proximity to the primary site (27). Gliomas treated with temozolomide often hypermutate at recurrence leading to treatment resistance, as evidenced by the mere 20% of recurring gliomas showing response to the same agent (17, 28). Dissemination beyond the brain is uncommon, but some high grade gliomas may spread into the meninges or opposing brain hemisphere (17).

Besides traditional oncogenic drivers, gliomas are characterized by deregulated epigenetics and high levels of hypoxia (low oxygen), processes which are largely regulated by 2-OGDDs.

2-OGDD’S AND EPIGENETIC REPROGRAMMING

A significant proportion of 2-OGDDs in mammals are demethylases involved in epigenetic reprogramming (6, 29). Methylation and demethylation of DNA and histones are the fundamental processes guiding epigenetic inheritance and regulating transcriptional activation and repression (30, 31). Consequently, aberrant modifications to these epigenetic processes, causing hyper- and hypo-methylating events, have emerged as hallmarks of cancer progression (32, 33).
Demethylases regulate the epigenome through either the conversion of methylated cytosine (5-mC) to hydroxymethylcytosine (5-hmC) on DNA (Figure 2), or the removal of methyl groups from lysine residues on histones (Figure 3).

**Global Methylcytosine Status in Glioma**

Epigenetic modifications are considered key mechanisms regulating occurrence and prognosis of glioma (34), and are used as classifiers of glioma subtypes (15, 16). Early genome-wide 5-mC analyses revealed that many low-grade gliomas and secondary GBMs contained large numbers of hypermethylated loci referred to as the glioma CpG island methylator phenotype (G-CIMP), and this was closely associated with the presence of somatic IDH1 mutations, and improved prognosis (35–37). IDH1 mutations are considered to occur early during the genesis of glioma, persisting during progression to secondary GBM, but they rarely appear in primary GBM (24, 38). Although initial reports suggested that G-CIMP remains stable during disease progression (35, 37), more recent analyses have shown their loss upon recurrence of IDH1-mutant gliomas (39–42). Loss of G-CIMP at recurrence resembled genome-wide 5-mC patterns seen in IDH1 wild-type primary GBM, and was associated with poorer outcomes (41). A novel 7-CpG signature has been identified in non-G-CIMP primary GBMs, where high-risk signatures correlated with poorer overall survival in patients treated with temozolomide and radiation (43), suggesting that even in the absence of G-CIMP and IDH1 mutations, 5-mC marks may be prognostic.

Interestingly however, earlier approaches for quantifying methylation, such as those used in the identification of G-CIMP (35, 36), relied on bisulfite conversion techniques, which cannot differentiate between 5-mC and 5-hmC. It was the introduction of oxidative bisulfide chemistry that made the distinction between 5-mC and 5-hmC possible (44), and consequently, led to the discovery of 5-hmC-specific binding proteins that are not only involved in DNA repair, but also transcriptional regulation (45, 46). These findings suggest that 5-hmC, in addition to being an intermediate in DNA demethylation, may have its own unique epigenetic role.

Many studies report a loss of global 5-hmC content in glioma compared to healthy brain tissues (47–52). Clinically, lower levels of 5-hmC have been associated with high tumor grade and poorer prognosis in glioma (48, 50, 53). More recent investigations moved beyond measuring global 5-hmC levels, to delineate, with base resolution, specific genomic locations to show 5-hmC patterns; all reporting higher than expected levels of 5-hmC at intronic CpG dinucleotides of high-grade gliomas and GBMs (50, 51, 54). Higher intronic 5-hmC levels correlated with elevated expression of the corresponding gene (54), with 5-hmC levels enriched within enhancer elements (50, 54), and 5-hmC levels associated with histone marks for open chromatin (50, 51). Thus, despite global loss of 5-hmC, genomic locations associated with transcriptional regulation and expression were commonly enriched for 5-hmC in glioma.

**Ten-Eleven Translocases (TETs)**

The TET family consists of three members (TET1/2/3). TET enzymes are involved in both passive and active DNA demethylation (55). During active DNA demethylation, oxidized cytosine intermediates (5-hmC) are excised by thymine DNA glycosylase and repaired with base-excision repair (BER) to generate an unmethylated cytosine (56, 57) (Figure 2). Passive DNA demethylation on the other hand occurs...
during cell replication, when 5-mC at CpG sites are not recognized and replaced with unmethylated cytosine (58). In humans, TET1 is located on chromosome 10q21.3, TET2 on chromosome 4q24, and TET3 on chromosome 2p13.1. It is noteworthy that 10q21.3 is commonly deleted in gliomas (59–61).

TET2 is the most studied isoform in glioma. In comparison to normal human brain tissue, TET2 gene and protein expression is reduced in GBM and other gliomas (62, 63). TET2 expression is significantly decreased with increased grade, and lower TET2 was associated with poorer overall survival (62). Similar observations have been reported for the other two isoforms (53). In glioma, reduction in TET3 expression was associated with a genome-wide reduction in 5-hmC levels compared to normal brain, and decreased TET3 expression correlated with poorer prognosis (64). Together, these findings imply a tumor suppressive role for TET enzymes in glioma.

Numerous studies highlight the potential mechanisms by which TET expression and activity are dysregulated in gliomas. A likely mechanism for reduced TET activity is the indirect inhibition via mutated IDH1/2 (65). Mutant IDH1 enzymes often exhibit neomorphic activity, converting isocitrate into 2-hydroxyglutarate (2-HG), instead of 2-OG, which is required for TET activity (66, 67). In IDH1-mutant gliomas it has been suggested that 2-HG generation is responsible for the presence of G-CIMP, likely due to reduced TET demethylase activity (35, 36). Independent of IDH status, a complete absence of 5-hmC immunoreactivity was associated with nuclear exclusion of TET1 in 61% of gliomas (52). Transcription of TET2 may be repressed by zinc finger E-box-binding homeobox 1 (ZEB1) in gliomas. ZEB1 levels were inversely correlated with TET2 levels in tumors, and physical binding of ZEB1 to the TET2 promoter in glioma cells was observed in vitro (62). However, reductions in TET2 expression and activity are unlikely to be due to TET2 mutations, as direct sequencing of TET2 revealed very few mutations and minimal association of mutations with levels of 5-hmC in gliomas (68, 69). In humans, intragenic CpG sites within TET2 showed higher levels of 5-mC and lower levels of 5-hmC in GBM compared to normal brain, although within the TET2 promoter low levels of both 5-mC and 5-hmC were detected at CpG sites of normal brain and GBM (63). Therefore, it is unlikely that lower TET2 expression in glioma is transpiring as a result of promoter methylation-mediated transcriptional suppression, but may be an effect of transcription prevention due to intragenic DNA methylation. Interestingly though, in a cohort of low-grade gliomas that had promoter hypermethylation, all were wild-type IDH1/2 (68). From this we hypothesize that in the absence of IDH1/2 mutations, a small portion of IDH wildtype tumors may instead remodel TET2 promoter methylation in an attempt to disrupt TET2 activity. Taken together, these studies demonstrate the tumor suppressive role of TET enzymes in glioma, and highlight the potential mechanisms by which TET expression and activity may be dysregulated. Restoration of TET function to resemble healthy brain tissue may aid in regulating epigenetic processors that can counteract glioma progression and improve treatment outcomes.

**Jumonji-C Domain Containing Histone Demethylases**

Many 2-OGDDs are from the large family of evolutionary conserved jumonji-C (JmjC) domain-containing proteins that...
are responsible for catalysing the removal of methyl groups from lysine residues on histones (29, 70) (Figure 3). There are several subfamilies of JmjC domain-containing histone lysine demethylases with substrate specificity to different methylated lysine residues, and this specificity is mediated by the functional domains unique to each subfamily (2, 29). The dynamic interplay between histone methylation and demethylation can result in either gene activation [via histone 3 lysine 4 (H3K4), H3K36 and H3K79] or inactivation (H3K9 and H3K27) (71, 72).

JmjC-domain containing demethylase isoforms are heterogeneously expressed in different brain locations and adult brain cell types (73, 74). Under hypoxic conditions, JMJD3 expression increased in neurons (75), but the modulation of specific histone methylation marks in response to varying oxygen tensions, and ranges of iron and 2-OG levels in brain cells, has yet to be determined.

In gliomas, changes in JmjC-dependent demethylase expression have been associated with differences in genome-wide histone methylation patterns (76, 77), and lower global histone methylation was associated with poorer patient survival (78). Conflicting reports on expression patterns of JmjC-dependent demethylases in glioma and GBM tissues have been published (77, 79–83). Overall, whether JmjC-dependent demethylases promote or suppress gliomagenesis is likely enzyme-dependent, although the majority of studies show these enzymes to promote tumor progression.

Introduction of the IDH1R132H mutation in astrocytoma cells has been associated with both global histone hypermethylation (84), and enrichment of specific histone methylation marks (85). Mutant IDH1 enzymes generate the oncometabolite 2-HG instead of 2-OG, and 2-HG has been shown to competitively inhibit histone demethylase activity (65, 86). Despite the fact that reduced histone demethylase activity has been linked with higher histone methylation in astrocytoma cells, most clinical gliomas show increased levels of JmjC-dependent demethylases and lower histone methylation (76–81). Thus, further investigations of the biological mechanisms causing increased expression of JmjC-dependent demethylases in glioma is needed.

2-OGDDs AND THE HYPOXIC PATHWAY

Gliomas are highly hypoxic tumors and this is associated with poor patient prognosis (23, 87–89). Hypoxia induces adverse tumor characteristics including genomic instability, decreased apoptotic potential, increased expression of oncogenes and increased angiogenesis, which have all been described in gliomas (90). These characteristics are driven by the hypoxia inducible factors (HIFs) which are regulated by microenvironmental oxygen levels and the 2-OGDD enzymes, prolyl hydroxylases (PHD) and factor inhibiting HIF (FIH) (Figure 4) (91). As these HIF hydroxylases are dependent on oxygen for optimal function their activity is likely impaired in gliomas (92–95).

HIFs (HIF-1,2,3) are heterodimeric transcription factors, consisting of one of three oxygen-sensitive α-subunits and a constitutive β-subunit (also known as aryl hydrocarbon receptor nuclear translocator (ARNT)) (97–99). HIF-1α is located on chromosome 14q23 (100); HIF-2α, also known as endothelial PAS domain protein 1 (EPAS1), is on 2p21, and HIF-3α is on 19q13 (101). Active HIF complexes accumulate in the nucleus and bind to specific hypoxic response elements (HREs) in promoter regions of HIF target genes, inducing their expression (102, 103). HREs contain the consensus sequence 5′CGTG3′, targets of CpG methylation, and CpG methylation blocks HIF-1 binding and transactivation (104). Even though HIF-1 and HIF-2 have identical HREs, their response to hypoxia, tissue distribution, target genes and their pro- or anti-tumor effects are distinct (105). Binding of HIF-1 and HIF-2 to their canonical HREs vary according to histone modifications, with HIF-1 preferentially associating with H3K4me3 modifications and HIF-2 with H3K4me1 (106). These binding patterns were interpreted as HIF-1 binding predominantly at regulatory regions within promoters, and HIF-2 binding to enhancer regions (106).

HIF’s modulate expression of hundreds of genes, and as a result, promote tumor growth and spread, adaptation to the tumor microenvironment, and resistance to chemo- and radiotherapy (107, 108). HIF activity also affects DNA methylation, histone acetylation and regulates noncoding RNAs (109), demonstrating the complexities of the hypoxic pathway.

HIF-1α has been proposed to drive glioma progression from low-grade astrocytoma to high-grade GBM (23, 110). Higher HIF-1α expression in human astrocytoma and GBM has been correlated with worse prognosis (111–114). Moreover, expression of HIF-1α, and its downstream target genes vascular endothelial growth factor (VEGF), glucose transporter (GLUT1), and carbonic anhydrase (CA9), show increased expression in higher grade gliomas compared to lower grade (115). In addition, increases in VEGF expression were shown to localize to hypercellular and necrotic regions that form as result of decreased oxygen and nutrient delivery (113, 116).

In comparison to HIF-1α, HIF-2α may be a specifically attractive target in GBMs, as it is expressed in glioma stem cells but not normal neuronal progenitors and it is activated by long-term hypoxia, in addition to its association with poor patient survival (117).

HIF Hydroxylases

HIF activity is regulated at the post-translational level by two families of HIF hydroxylases, the prolyl hydroxylase domain (PHD) and factor inhibiting HIF (FIH) 2-OGDDs (Figure 4). PHDs hydroxylate specific proline residues on the HIF-α subunit targeting the subunit for proteasomal degradation (9, 92, 118). FIH hydroxylates an asparagine residue and prevents binding of the co-activators CBP/p300 and nuclear translocation (93, 119). The instability of HIF-α and the inhibition of transcriptional activators binding results in a reduction in both HIF-α protein and expression of target genes. Protein hydroxylation was considered irreversible, but a recent study showed evidence that FIH-mediated asparagine hydroxylation may be reversible by as yet unknown cellular enzymes (120).

Hypoxia-Inducible Factors

Hypoxic conditions typical of most solid tumors result in accumulation of the HIF transcription factors (11, 96). The
The PHDs and the FIH enzymes have specific roles in oxygen and metabolic sensing due to their exquisite requirements for molecular oxygen and 2-OG, respectively (11). PHDs have higher affinity for oxygen (9, 13), bind unusually tightly to Fe²⁺ (121), and have a lower affinity for ascorbate compared to FIH (3), possibly due to the narrower opening to the enzyme active site of PHDs (122). PHD2 and FIH bind 2-OG with distinct residues, with FIH sharing more homology with JmjC-domain containing protein family of enzymes (94), suggesting evolutionary divergence (122). The HIF hydroxylases therefore have different sensitivities to loss of enzyme substrates and/or co-factors.

PHD2 (encoded by \textit{EGLN1}) is generally acknowledged as the primary mediator of HIF-1α protein degradation, with PHD1 and 3 more likely to be involved in fine-tuning of the hypoxic response (123). This may be reflected in the subcellular localisation of each isoform, with PHD1 detected exclusively in the nucleus, PHD2 (and FIH) in the cytoplasm, and PHD3 in both compartments (124). Interestingly, PHD2 is activated, rather than inhibited, by the R-enantiomer of 2-HG as it mimics 2-OG, suggesting that IDH mutations may lead to HIF-α degradation (125–127). It has been shown, using immunohistochemistry, that HIF-1α and IDH²¹³²¹⁷ expression are not related, supporting the ability of 2-HG to activate PHD2 (128).

\textit{FIH} (also known as \textit{HIF1AN}) is mapped to chromosome 10q24 (93). Full or partial deletions of chromosome 10q often occur in gliomas, and the frequency of these deletions increases with tumor grade (59–61). Thus, \textit{FIH} mRNA expression often decreases with increasing tumor grade (129, 130). Investigation of \textit{FIH} in GBMs has shown that \textit{FIH} reduces the interaction between p300 and HIF-1α which is essential for transcriptional activity (131), and correspondingly higher \textit{FIH} expression was associated with reduced \textit{GLUT1} and \textit{VEGF} expression in GBM cells (131). Loss of \textit{FIH} through deletion of chromosome 10q24 may increase the hypoxic response, and thus contribute to an aggressive and treatment resistant glioma phenotype associated with hypoxia (23, 87, 88). While PHD2 is activated by the mutant IDH metabolite, 2-HG, FIH is inhibited, resulting in p300 interacting with HIF-α and inducing target gene expression (125). However, FIH has been shown to interact with a glioma tumor suppressor gene (\textit{ANKDD1A}), which increased FIH activity, thereby reducing HIF-α activation and preventing HIF target gene expression (132).
SUBSTRATE AND COFACTOR REQUIREMENTS OF 2-OGDDs

2-OGDDs contain a non-heme iron (Fe$^{2+}$) in the active site, and utilize 2-OG (also known as α-ketoglutarate) and molecular oxygen as substrates (Figure 5). Ascorbate is an essential cofactor, and is thought to be required to maintain the active site Fe$^{2+}$ in the reduced state (11–14, 133, 134).

Molecular Oxygen as 2-OGDD Substrate and its Availability in Gliomas

Oxygen is an absolute requirement for all 2-OGDDs, but not all 2-OGDDs function as oxygen sensors. The PHDs have a $K_m$ for oxygen of 230–250 μM, slightly above dissolved oxygen concentrations in air (20.9% O$_2$ in gas phase ~ 200 μM dissolved O$_2$) (135), and this property makes these proteins the predominant cellular oxygen sensors. These $K_m$ values are significantly greater than for FIH at 90 μM, and the collagen prolyl 4-hydroxylases (C-P4H) at 40 μM (13, 135, 136).

Tissue partial pressure of oxygen (PO$_2$) in the human body range from 104–108 mmHg in the alveola of the lung, to arterial PO$_2$ of 90 mmHg and venous PO$_2$ of 40 mmHg, to most tissues that have between tissue PO$_2$ of 20–70 mmHg (137). Oxygen levels in the brain are heterogeneous and difficult to measure, with levels of 30–48 mmHg in normal brain recorded. Hypoxia is defined as <5 mmHg, and levels below 2.5 mmHg are known to...
induce clinical radioresistance (138–145). Theoretical modelling suggests the minimum oxygen level requirement for brain tissue is 17 mmHg and that a critical range for hypoxic injury is 4–11 mmHg (140).

Hypoxia is a prominent feature of gliomas. Oxygen levels in tumors have been measured using a range of techniques, including injection of hypoxia markers (146–149), direct measurements using polarographic O₂ microelectrodes (145, 150) and MRI/CT scans (151). Using these techniques, oxygen levels were observed to be lower in gliomas and peritumoral regions compared to normal brain tissues, and readings below 2.5 mmHg were more common in tumors of increasing grade (145, 150, 152), with the most severe hypoxia detected in GBMs (23, 88, 89). A review of six studies reported a median PO₂ of 13 mmHg in gliomas (144). This suggests that in high grade gliomas, the activity of 2-OGDD enzymes is likely to be reduced, but hypoxia is not routinely measured.

As ionizing radiation remains the mainstay of glioma treatment, and since hypoxia governs radioresistance, considerable clinical effort has been focused on reducing tumor hypoxia. With regards to 2-OGDD activity, these strategies may also improve enzyme activity, and are thus briefly discussed here. In an attempt to improve tumor oxygenation, patients have been given pure oxygen in a pressurized environment (hyperbaric oxygen) to breath (153). Alternatively, patients breathed 95% O₂ with 5% CO₂ (carbogen), which, together with hypercapnic-induced vasodilation, increases the amount of dissolved plasma O₂ at the capillary level (154). Carbogen was tested in combination with nicotinamide, which is believed to prevent transient cessations in blood flow, thus inhibiting the development of acute hypoxia (154). Drugs have been developed to improve oxygen delivery (eg trans sodium crocetinate, TSC) (155), to normalize the tumor vasculature (e.g., anti-VEGF bevacizumab) (156), or to reduce oxygen consumption rate via mitochondrial poisons (e.g., anti-parasitic drugs atovaquone, ivermectin, proguanil, mefloquine, and quinacrine) and tested in patients with GBM (157). Overall, the results of these clinical trials have been disappointing and none of the approaches have been adopted into clinical practice, and actual oxygen measurements were largely lacking.

### 2-Oxoglutarate and Oncometabolites as 2-OGDD Substrates in Gliomas

The substrate 2-oxoglutarate (2-OG) is a product of the reaction in which isocitrate dehydrogenase enzymes (IDH) convert isocitrate to 2-OG (Figure 5). This reaction occurs in the TCA cycle via IDH3 and in the cytosol via IDH1 and IDH2. A number of IDH1 and IDH2 mutations have been reported in glioma, with the most common a base substitution in codon 132 of IDH1 resulting in an arginine to histidine replacement (IDH1R132H) (24, 67). IDH1R132H has been identified in more than 70% of grade II/III astrocytic and oligodendrogial diffuse gliomas, and in more than 80% of secondary GBM, but rarely in primary GBM (24, 158, 159). IDH1R132H enzymes generate 2-HG, instead of 2-OG (66, 67), which binds competitively to 2-OGDD enzymes and inhibits their function (Figure 5). Studies have, however, also reported that accumulation of 2-HG does not universally occur in all IDH1R132H and, conversely, that some wild type IDH cells accumulate 2-HG (160, 161). Further research is required to understand the impact of IDH mutations on patients with glioma, and how 2-HG accumulation interacts with other 2-OGDD substrates and co-factors to influence their activity in these tumors.

In gliomas with IDH1R132H mutations, drugs that inhibit the mutant IDH1 enzymes may improve 2-OGDD activity by reducing 2-HG production. A number of mutant IDH1 inhibitors are currently being evaluated in clinical trials with glioma patients, including AG-120 (Ivosidenib), AG-881 (Vorasidenib), BAY1436032 (Bayer), and DS-1001b (NCT02746081) (162–166). Pre-clinical investigations have reported anti-proliferative effects, reductions in tumor growth rates, and lower levels of 2-HG in both glioma cells and tumors from animal models (167–170). To date, 2-HG levels have only been measured in the plasma of human glioma patients following intervention with Ivosidenib, reporting no difference compared to those without treatment (163). Despite this, interest remains high and data from a Phase I study of Ivosidenib and Vorasidenib in patients with recurrent, non-enhancing, IDH1-mutant, low-grade glioma is currently pending (162). In addition to inhibitors, vaccines against mutant IDH1 have been tested in mice (171, 172). Mice with mutant IDH1R132H gliomas treated with the vaccine showed longer survival than non-immunized mice, and had higher levels of peripheral anti-IDH1R132H antibodies, IFN-γ, and CD8+ T cells (172). However, 2-HG levels in tumors were not measured, and thus the vaccine effect on 2-OGDDs remains to be tested.

### Iron as Cofactor for 2-OGDDs and Availability in the Brain

Iron is the most abundant transition metal in the brain (173) and is more concentrated in some regions than in others (range; 13.5–1.75 μmol/g dry weight) (174), including the iron-rich substantia nigra, caudate nucleus and globus pallidus (175). Most gliomas arise in the frontal/temporal lobe, areas rich in glial cells and, potentially, relatively lower in iron. Astrocytes secrete hepcidin, which modulates the expression of ferroportin and other iron regulatory proteins, and thereby function as iron sensors to regulate and communicate the iron requirement of the brain through paracrine signaling (176–178).

Iron uptake into the brain is tightly regulated through the endothelial cells and neighboring astrocytes in the blood brain barrier (BBB) (176, 179, 180), primarily through the transferrin bound iron (TBI) pathway (174, 181, 182) however, when this pathway becomes saturated, non-TBI pathways are used (183). Through the canonical TBI uptake pathway, ferric iron (Fe³⁺) forms halotransferrin (174), which is able to pass through the BBB by binding to transferrin receptors on the apical surface of brain microvascular endothelial cells (BMVECs). Within the BMVEC, excess iron is stored in the cytosolic labile iron pool, which is the principle source of metals for metabolism (184). Efflux of iron through the abluminal membrane into the brain interstitium occurs through ferroportin (185, 186), expressed on...
the basolateral side of the BMVEC cells (186, 187). Once iron has crossed the BBB barrier, it is taken up by neurons, astrocytes, oligodendrocytes and microglia through TBI and nonTBI uptake pathways (183).

Iron plays a role in carcinogenesis, with proteins that modulate and regulate iron metabolism often dysregulated in gliomas (188–191). GBM cancer-stem-like cells were shown to upregulate transferrin expression, and to extract iron more effectively from the tumor microenvironment than non-stem-like tumor cells in an ex vivo explant model (192). The Fe2⁺ content in gliomas has not been reported but reduced levels may impede 2-OGDD function in tumors and cancer stem cells.

**Ascorbate as Cofactor for 2-OGDDs and its Availability in the Brain**

As a cofactor for 2-OGDDs, ascorbate acts to reduce Fe³⁺ back to active Fe²⁺ (Figure 5). This activity appears to be specific to ascorbate as alternative reducing agents such as glutathione or N-Acetylcysteine are unable to substitute for ascorbate in 2-OGDD activity (12, 193, 194). Ascorbate is also involved in stabilizing cysteine residues in PHD enzymes, preventing intramolecular oxidation and supporting catalytic activity (126).

Normal brain tissue has one of the highest ascorbate levels of all tissues in the body, reaching intracellular concentrations of 2–10 mM depending on the cell type (195–197). In times of ascorbate insufficiency, the brain is one of the last tissues to lose ascorbate, supporting its importance to brain function (195, 198). The specific vitamin C transporters (sodium-dependent vitamin C transporters) are not expressed on the endothelial cells lining the BBB (198), and ascorbate enters the central nervous system through the choroid plexus where it can diffuse through the cerebrospinal fluid to the brain (195, 198). Cells within the brain express ascorbate transporters allowing intracellular ascorbate accumulation (198).

Data on ascorbate content in gliomas is limited to a single study that reported ascorbate levels in astrocytomas from eleven patients (199). While ascorbate levels were not different between astrocytoma tissue and non-neoplastic tissue, DNA content was significantly higher in astrocytoma (tumor) tissues indicating increased cell density (or cellularity) of the tissues. This suggests that intracellular ascorbate per cell may be reduced in astrocytoma tissue compared to normal, non-neoplastic tissue (199). These intriguing findings need to be confirmed.

**Ascorbate and Epigenetic Reprogramming**

Evidence for the effects of ascorbate on epigenetic reprogramming is largely from embryonic cells (200, 201), but data in gliomas is missing. In patients with myeloid malignancies, oral ascorbate supplementation resulted in an increase in the ratio of 5-hmC compared to 5-mC in mononuclear myeloid cells (202). Here, DNA demethylation was not associated with changes in TET expression (202, 203), but instead appear to result from ascorbate-mediated restoration of endogenous TET activity, which was supported by studies with TET2-deficient mice (204). Gliomas show lower TET expression independent of TET mutations (63, 68, 69), and we hypothesize that ascorbate may compensate for lower TET expression by upregulating residual TET2 function as was observed in a case study of acute myeloid leukemia (205).

Low-grade primary gliomas commonly harbor IDH mutations that persist during progression to secondary GBM (24). In vitro, ascorbate was able to circumvent competitive inhibition by 2-HG in colon cancer and HOXA9-immortalized mouse bone marrow cells with IDH1R132H mutations (206, 207). One in vitro study reported the effects of ascorbate on epigenetic marks in LN229 glioma cells, showing increased TET3 mRNA expression, as well as increased 5-hmC, but these cells did not harbor an IDH mutation (64). Yet, these findings, together with reported associations between higher 5-hmC levels and better prognosis in patients with GBM (50), support the notion that sufficient ascorbate levels in glioma tumors may induce demethylation activity and promote more favorable outcomes, although whether sufficient ascorbate can overcome high levels of 2-HG remains to be determined.

In addition to TET-mediated effects, ascorbate induced H3K9me2/3 and H3K36me2/3 demethylation via JmjC-dependent demethylases in embryonic stem, embryonic fibroblast and Th17 cells from mice (208–210). Ascorbate caused reductions in H3K9 methylation and increased expression of the JmjC-dependent demethylases, JHDM2A-C and JHDM3B, as well as widespread DNA demethylation at CpG island boundaries in human embryonic stem cells (211). However, investigations in gliomas are lacking, despite the well-established link between glioma formation and global 5-hmC deficiency.

**Ascorbate and the Hypoxic Pathway**

The relationship between intracellular ascorbate levels and HIF pathway activity has been investigated in numerous cancers, but not yet in gliomas. In vitro investigations of intracellular ascorbate levels and HIF pathway activity have been performed in varying cancer types, findings from which have guided further in vivo studies (212–215). In relevant mouse models (using ascorbate-dependent Gulo−/− mice), increased ascorbate intake or administration was associated with increased tumor ascorbate levels, reduced HIF pathway activity and reduced tumor growth (216). In clinical samples of endometrial (217), colorectal (218), thyroid (214), papillary cell renal cell carcinomas (215, 219), and breast cancer (220), high tumor ascorbate levels were associated with low HIF-1α protein levels and low HIF target gene expression. This relationship was not evident in clear cell renal cell carcinoma (215, 219), that have a mutated von Hippel-Lindau factor which prevents proteasomal degradation of hydroxylated HIF-α (219). Higher levels of tumor ascorbate were associated with improved disease-free survival in patients with colorectal cancer (218) and improved disease-specific survival in patients with breast cancer (220).

**HIGH DOSE ASCORBATE AS CANCER TREATMENT**

Infusion with high dose ascorbate as an alternative or complementary therapy for cancer is widespread (221), but
lacks evidence of efficacy (222, 223), despite early promising data (224, 225). Since then, pharmacokinetic data have demonstrated that infusion results in supra-physiological plasma ascorbate levels that are not achievable by oral administration (226–229). Case studies and small clinical trials continue to surface that suggest there may be circumstances under which high dose ascorbate infusion can provide a clinical benefit (230–239).

Preclinical Models of High Dose Ascorbate Treatment in Gliomas

In a mouse xenograft glioma model, analysis of ascorbate levels in plasma, tumor, and cerebrospinal fluid samples showed that ascorbate increased 1 h post intraperitoneal injection with 4 g/kg of ascorbate (240). One study, using an intracranial GL261 glioma mouse model, reported that radiation treatment slowed tumor growth, whereas ascorbate treatment made no difference, and the combination of ascorbate and radiotherapy induced faster progression (241), in conflict to in vitro findings of radio-sensitisation by ascorbate in numerous glioma cell lines, including GL261 cells (242–244). However, ascorbate levels in the intracranial model were not measured, and thus the impact of ascorbate on glioma response to radiation remain uncertain.

Clinical Trials in Patients With Gliomas and GBMs

Preclinical data led to phase I clinical trials administering intravenous ascorbate to glioma patients, with and without standard radiotherapy and temozolomide (245). High dose vitamin C (HDVC) was found to be safe and well tolerated, reaching target 20 mM plasma levels (240, 245), but tumor ascorbate levels were not measured. A trend of improved overall survival was reported, but participant numbers were too small to determine statistical significance (240). Two case reports for the use of HDVC infusions in patients with glioma have also been reporting (237, 246).

Previous research has shown an association between a lower proportion of methylation at the O-6-methylguanine-DNA methyltransferase (MGMT) promoter in glioma tumors and poorer patient prognosis (247). MGMT is a DNA repair enzyme responsible for resistance to temozolomide, and hypermethylation of the MGMT promoter is evident in 40–45% of gliomas (248, 249), with higher methylation levels in low-grade gliomas compared to GBMs (53). Interestingly, in glioma patients with low methylation levels at the MGMT promoters, HDVC infusions resulted in improved overall survival (240), but unfortunately, ascorbate levels in the glioma tissue were not measured. Plasma ascorbate levels do not necessarily reflect tumor ascorbate levels due reduced functioning vasculature and BBB in gliomas. Overall, the clinical worth of HDVC in cancer remains unproven.

CONCLUSION

The superfamily of 2-OGDD enzymes play a vital role in glioma progression and patient prognosis, being involved in epigenetic modifications and oxygen sensing. Limiting supplies of one or more of their substrates or cofactors in gliomas is likely although reported measurements are rare. Restoration of epigenetic modifications offers a promising target in the treatment of cancer, as these alterations are reversible, as opposed to genetic mutations. Attempts at increasing tumor oxygenation to improve effectiveness of radiation and chemotherapy in glioma are not (yet) in clinical practice (250), and new strategies are sought. Ascorbate infusion is a safe and cheap option that may be able to normalize 2-OGDD function in a subset of glioma tumor subtypes. However, this will likely depend on mutation status and on the ability to increase intracellular ascorbate levels in these tumors. Future research will need to confirm ascorbate status of clinical glioma tumors, on measuring 5-hmC levels and HIF activity in clinical samples, and on determining an optimal ascorbate dose for patients, before embarking on phase III trials to determine clinical efficiency.

AUTHOR CONTRIBUTIONS

Conceptualization, RC, EB, JR, and GD. Funding acquisition, EP and GD. Supervision, EP, MV, and GD. Writing—original draft, RC and EB. Writing—review and editing, JR, MV, and GD. All authors contributed to the article and approved the submitted version.

FUNDING

We received funding from the Mackenzie Charitable Foundation (EP and GD), the Canterbury Medical Research Foundation (RC, EP, and GD) and the University of Otago (RC and GD).

ACKNOWLEDGMENTS

We would like to acknowledge receipt of the doctoral scholarship from the University of Otago (EB).
2-oxoglutarate dependent dioxygenases in gliomas.

Huang WJ, Chen WW, Zhang X. Glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. (2006) 20:E5. doi: 10.3171/foc.2006.20.2.E5

Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JR, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature (2020) 580:517–23. doi: 10.1038/s41586-020-2209-9

Dong C, Zhang H, Xu C, Arrowsmith CH, Min J. Structure and function of dioxygenases in histone demethylation and DNA/RNA demethylation. IUCr(2014) 1:340–9. doi: 10.1016/S2052-2551(14)020922

Shi Y. Histone lysine demethylases: Emerging roles in development, physiology and disease. Nat Rev Genet (2007) 8:829–37. doi: 10.1038/nrg2218

Fu Y, He C. Nucleic acid modifications with epigenetic significance. Curr Opin Chem Biol (2012) 16:516–24. doi: 10.1016/j.copcb.2012.10.002

Berdasco M, Esteller M. Developmental Cell Review Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Aways. (2010) 19:699–711. doi: 10.1016/j.devcel.2010.05.005

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

Gusatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol (2018) 51:50–8. doi: 10.1016/j.semcancer.2017.11.010

Noushmrer H, Weisenser DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG Island Methylator Phenotype That Defines a Distinct Subgroup of Glioma. Cancer Cell (2010) 17:510–22. doi: 10.1016/j.ccr.2010.03.017

Turcan S, Rohde D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 483:473–89. doi: 10.1038/nature10866

Laffaire J, Everhard S, Idbaui A, Crinière E, Marie Y, de Reyniès A, et al. Methylpyrimidine profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol (2011) 13:848–98. doi: 10.1093/neuonc/noq110

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. Integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321:1102–7. doi: 10.1126/science.1164382

Bai H, Harmananci AS, Eron-Özay EZ, Li J, Côkşun S, Simon M, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet (2015) 47:59–66. doi: 10.1038/ng.3457

Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, et al. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell (2015) 28:307–17. doi: 10.1016/j.ccell.2015.07.012

de Souza CF, Sabedot TS, Malta TM, Steetson L, Morozova O, Sokolov A, et al. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotype That Defines a Distinct Subgroup of Glioma. Cancer Cell (2010) 17:510–22. doi: 10.1016/j.ccr.2010.03.017

Nomura M, Saito K, Aihara K, Nagaie G, Yamamoto S, Tatsuno K, et al. DNA methylation is associated with malignant progression of lower-grade gliomas. Sci Rep (2019) 9:1–12. doi: 10.1038/s41598-019-43790-7

Yin AA, He Y-L, Etchevery A, Liu Y-H, Aubry M, Barnholtz-Sloan J, et al. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clin Epigenet (2019) 1:176. doi: 10.1186/s41388-019-0317-7

Booth MJ, Ost TWB, Berardi D, Bell NM, Branco MR, Reik W, et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat Protoc (2013) 8:1841–51. doi: 10.1038/nprot.2013.115

Spruijt CG, Gnerlich F, Smits AH, Pfaffenrader T, Jansen PWT, Bauer C, et al. Dynamic readers for 5-(Hydroxymethyl)cytosine and its oxidized derivatives. Cell (2013) 152:1146–59. doi: 10.1016/j.cell.2013.02.004

Iurlaro M, Ficz G, Oxley D, Raiber EA, Bachman M, Booth MJ, et al. A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol (2013) 14: doi: 10.1186/gb-2013-14-10-119

Jin S-G, Jiang Y, Qu R, Rauch TA, Wang Y, Schackert G, et al. 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations. (2011) 71:7360–5. doi: 10.1107/S0021962611043107

Kraus T, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, et al. Low values of 5-hydroxymethylcytosine (5hmC), the ’sixth base,’ are
associated with anaplasia in human brain tumors. *Int J Cancer* (2012) 131:1577–90. doi: 10.1002/ijc.27429

49. Kraus T, Kolck G, Greiner A, Schiel K, Guibourt V, Kretschmar HA, et al. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as a new epigenomic hallmark of glioblastoma. *Tumor Biol* (2015) 36:8439–46. doi: 10.1007/s13277-015-3606-9

50. Johnson KC, Houseman EA, King JE, Von Herrmann KM, Fadul CE, Christensen BC. 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients. *Nat Commun* (2016) 7:1–11. doi: 10.1038/ncomms13177

51. Fernandez AF, Bayó GF, Sierra MI, Urdinguio RG, Torá EG, García MG, et al. Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. *Orig Artic Hum Mol Genet* (2018) 27:3046–59. doi: 10.1093/hmg/ddy214

52. Waha A, Müller T, Gessi M, Waha A, Isselstein LJ, Luxen D, et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. *Am J Pathol* (2012) 181:675–83. doi: 10.1016/j.ajpath.2012.04.017

53. Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-Hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. *PloS One* (2012) 7:e41036. doi: 10.1371/journal.pone.0041036

54. Glowacka WK, Jain H, Okura M, Mainaitis AM, Mamajtan Y, Nejad R, et al. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. *Acta Neuropathol* (2018) 135:1617–34. doi: 10.1007/s00401-018-1821-3

55. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature* (2013) 502:472–9. doi: 10.1038/nature12750

56. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxy-cytosine and its excision by TDG in mammalian DNA. *Science* (2011) 333:1303–7. doi: 10.1126/science.1196786

57. Dalton SR, Bellacosa A. DNA demethylation by TDG. *Epigenomics* (2012) 4:459–67. doi: 10.2217/epi.11.236

58. Otani J, Kimura H, Sharif J, Endo TA, Mishima Y. Cell Cycle-Dependent Turnover of 5-Hydroxymethyl Cytosine in Mouse Embryonic Stem Cells. *PloS One* (2013) 8:e52961. doi: 10.1371/journal.pone.0082961

59. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, et al. Cartilage Differentiation Mediated by the Human Histone Demethylase Jumonji D3 as a Tumor Suppressor by Reversing IDH1 Mutations. *Cancer Res* (2013) 73:9038–45. doi: 10.1158/0008-5472.can-13-2140

60. Ichimura K, Ohgaki H, Kleihues P, Collins VP. Molecular pathogenesis of gliomas. *Brain* (2018) 152:235–40. doi: 10.1098/rb.2015.07.030

61. Lee HY, Choi K, H.Park, YK, Park H. HIF-1-dependent induction of jumonji domain-containing protein (JMJ) 3 under hypoxic conditions. *Mol Cells* (2014) 37:43–50. doi: 10.14348/molcells.2014.225

62. Lounnas A, Sievers C, Donoghue KJ, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. *Cell Stem Cell* (2017) 20:233–246.e7. doi: 10.1016/j.stem.2016.11.003

63. Li M, Cheng J, Ma Y, Guo H, Shu H, Huang H, et al. The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-MTOR signaling. *Cancer Cell Int* (2020) 20:101. doi: 10.1186/s12935-020-01177-z

64. Liu BL, Cheng JX, Zhang X, Wang R, Zhang W, Lin H, et al. Global histone modification patterns as prognostic markers to classify glioma patients. *Cancer Epidemiol Biomarkers Prev* (2019) 28:1988–96. doi: 10.1158/1055-9965.EPI-19-0545

65. Dai B, Hu Z, Huang H, Zhu G, Xiao Z, Wan W, et al. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21. *Biochem Biophys Res Commun* (2014) 454:221–7. doi: 10.1016/j.bbrc.2014.10.078

66. Banelli B, Carra E, Barbieri F, Würth R, Parodi F, PattaroZZ, et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. *Cell Cycle* (2015) 14:3148–9. doi: 10.1080/15354110.2015.1090663

67. Ibarber M, Rasmussen BD, Michaelson SR, Pedersen H, Jensen KE, Villingerhej M, et al. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. *Mol Oncol* (2018) 12:406–20. doi: 10.1016/j.ymolon.2018.06.007

68. Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M. JHDM1B/FRXL1 is a nuclear protein that represses transcription of ribosomal RNA genes. *Nature* (2007) 450:309–13. doi: 10.1038/nature06255

69. Ene C, Edwards L, Riddick G, Baysan M, Woolard K, Kottiarova S, et al. Histone Demethylation Jumonji D3 (JMJDS) as a Tumor Suppressor by Regulating p35 Protein Nuclear Stabilization. *PloS One* (2012) 7:e31407. doi: 10.1371/journal.pone.0031407

70. Lu C, Ward PS, Kapoor GS, Roble D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* (2012) 483:474–48. doi: 10.1038/nature10860

71. Turcan S, Makarov V, Taranda J, Wang Y, Fabius AW, Wu W, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. *Nat Genet* (2018) 50:62–72. doi: 10.1038/s41588-017-0001-z

72. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxylglutarate inhibits histone lysine demethylases. *Nat Prod Rep* (2011) 28:1219–38. doi: 10.1039/c0np00066e

73. Altmann M, Pilkington GJ, Malureanu PA. The role of hypoxia in glioblastoma invasion. *Cells* (2012) 1:34–64. doi: 10.3390/cells1040045

74. Van C, Muiz Svanman SR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with 1 8F-fluoromisonidazole positron emission tomography before radiotherapy:
Correlation with time to progression and survival. Clin Cancer Res (2008) 14:2622–30. doi: 10.1158/1078-0432.CCR-07-4995

89. Kayarz MV, Sanus GZ, Hninoglu H, Kaci T, Kemedere R, Atukeren P, et al. Expression of hypoxia inducible factor-1α in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci (2008) 15:1036–42. doi: 10.1016/j.jocn.2007.07.080

90. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudopropagation, and as a therapeutic target. J Neuro-oncol Neurooncol (2009) 92:317–35. doi: 10.1007/s11060-009-9827-2

91. Semenza GL. Defining the role of hypoxia-inducible factor-1 in cancer biology and therapeutics. Oncogene (2010) 29:625–34. doi: 10.1038/onc.2009.441

92. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIF-1α targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science (2001) 292:464–8. doi: 10.1126/science.1059817

93. Mahon PC, Hirota K, Semenza GL. HIF-1α: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev (2001) 15:2675–86. doi: 10.1101/gad.924501

94. Hewitson KS, McNeill LA, Riordan MV, Tian Y-M, Bullock AN, Welford T, et al. Expression of hypoxia-inducible factor 1 in human glioma: implications of hypoxia-inducible factor-1α and caveolin-1 overexpression in isocitrate dehydrogenase-null type glioblastoma multiforme. Oncol Lett (2017) 17:2867–73. doi: 10.3892/ol.2019.9929

95. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. Hypoxia-inducible factor 2α expression in glioblastoma multiforme and transitional meningioma. J Clin Neurosci (2008) 15:1036

96. Kaelin WG, Ratcliffe PJ. Oxygen Sensing by Metazoans: The Central Role of HIF-1α–HIF-2α Responses to Temozolomide. Front Oncol (2018) 8:249. doi: 10.3389/fonc.2018.00249

97. Keith B, Johnson RS, Simon MC. HIF1α expression of hypoxia-inducible factor 1α in brain tumors: Association with angiogenesis, invasion, and progression. Cancer (2000) 88:2606–18. doi: 10.1002/1097-0248(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W

98. Lo Dico A, Martelli C, Diciglie C, Lucignani G, Ottobrini L. Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide. Front Oncol (2018) 8:242. doi: 10.3389/fonc.2018.00242

99. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragousis J, et al. 2-Oxoglutarate Dependent Dioxygenases in Gliomas. Front Oncol | www.frontiersin.org March 2021 | Volume 11 | Article 619300
129. Womeldorff M, Gillespie D, Jensen RL. Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma. *Neurosurg* Focus (2014) 37:1–17. doi: 10.3171/ 2014.9.FOCUS14466

130. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. *Neoplasia* (2004) 6:1–6. doi: 10.1016/S1528-006X(04)80047-2

131. Wang E, Zhang C, Polavaram N, Liu F, Wu G, Schroeder MA, et al. The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme. *Proc One* (2014) 9:e86102. doi: 10.1371/journal.pone.0086102

132. Feng J, Zhang Y, She, Xun F, Yan L, Ren X, et al. Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1α stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment. *Oncogene* (2019) 38:103–19. doi: 10.1038/s41388-018-0423-9

133. Kuiper C, Vissers MCM. Ascorbate as a cofactor for Fe-and 2-oxoglutarate dependent dioxygenases: Physiological activity in tumour growth and progression. *Front Oncol* (2014) 4:359. doi: 10.3389/fonc.2014.00359

134. Rebouche, Charles J. Ascorbic acid and carnitine biosynthesis. *Am J Clin Nutr* (1991) 54:611–5. doi: 10.1093/ajcn/54.6.61175

135. Hirslø M, Koivunen P, Günzler V, Kivirikko KI, Mälkilä, J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J Biol Chem* (2003) 278:30772–80. doi: 10.1074/jbc.M304982200

136. Mälkilä, J. Prolyl hydroxylases and tumor hypoxia. *FASEB J* (2003) 17:1183–45. doi: 10.1096/fj.02-3604

137. Ortiz-Prado E, Dunn JF, Vasconez J, Castillo D, Viscor G. Partial pressure of oxygen in the human body: a general review. *Anesthesia Analg* (1999) 88:528–62. doi: 10.1213/00000539-199960300-00027

138. Assad F, Schultheiss R, Leniger-Follert E, Wüllenweber R. Measurement of local oxygen partial pressure (PO2) of the brain cortex in cases of brain tumors. *Surg Neurol* (1993) 59:58. doi: 10.1097/00006123-199811000-00045

139. Meixensberger J, Dings J, Kuhniggk H, Roosen K. Studies of tissue PO2 in normal and pathological human brain cortex. *Acta Neurochir Suppl (Wien)* (1993) 59:58–63. doi: 10.1007/8-3-7091-9334-1_10

140. Dings J, Meixensberger J, Jäger A, Roosen K. Clinical Experience with 118 Brain Tissue Oxygen Partial Pressure Catheter Probes. *Acta Neuropathol* (1998) 43:1082–94. doi: 10.1007/s00415-0000123-34-11. doi: 10.1007/s10637-002-0022-3

141. Vaupeil P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using po2 histogram. *Antioxid Redox Signaling* (2007) 9:1221–35. doi: 10.1089/ars.2007.1628

142. Rampling R, Crucickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. *Radiat Oncol Biol Phys* (1994) 29:427–31. doi: 10.1016/0306-3016(94)90432-4

143. Qin Y, Von Eynben R, Liu Y, Chin FT, Miao Z, Apte S, et al. 18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. *Int J Radiat Oncol Biol Phys* (2018) 102:1183–92. doi: 10.1016/j.ijrobp.2018.06.287

144. Malki P, Mathis CA, Prados M, Gilbert JC, Budinger TF. Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. *Arct J Nucl Med* (1993) 33:2133–7.

145. Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang WT, et al. The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: A pilot study. *Transl Oncol* (2010) 3:160–9. doi: 10.1593/tlo.09265

146. Qian Y, Von Eyben R, Liu Y, Chin FT, Miao Z, Apte S, et al. *18F-EF5 PET-Based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy*. *Int J Radiat Oncol Biol Phys* (2018) 102:1183–92. doi: 10.1016/j.ijrobp.2018.06.287

147. Shan S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. *Br J Cancer* (2020) 122:1580–9. doi: 10.1038/s41416-020-0814-x
pre-clinical discovery assays. Sci Rep (2017) 7:12758. doi: 10.1038/s41598-017-12630-x

168. Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene (2019) 38:6835–49. doi: 10.1038/s41388-019-0929-9

169. Nicolay B, Narayanaswamy R, Amatangelo MD, Aguado E, Nagaraja R, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 3:4. doi: 10.1186/s40478-014-0180-0

170. Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, et al. Pan-mutant IDH1 inhibitor BAY 1436632 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol (2017) 135:629–44. doi: 10.1007/s00401-017-1677-y

171. Pellegatta S, Valletta L, Corbetta C, Patane A, Zucca I, Riccardi Sirtori F, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Ann Oncol (2019) 30:356. doi: 10.1093/annonc/mdz452.029

172. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell (2015) 28:441–55. doi: 10.1016/j.ccell.2015.09.002

173. Magri S, Pinton L, Masetto E, Cassandro S, Pozzuoili A, Belluzzi E, et al. Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients. Ann Oncol (2019) 30:356. doi: 10.1093/annonc/mdz452.029

174. Bradbury MW. Transport of iron in the blood-brain-cerebrospinal system. Mov Disord (2007) 21:1299. doi: 10.1002/mds.21020

175. Berg D, Hochstrasser H. Iron metabolism in parkinsonian syndromes. Mov Disord (2006) 21:1299–310. doi: 10.1002/mds.21020

176. Beydoun R, Hamood MA, Gomez Zubieta DM, Kondapalli KC. Na+/H+ exchanger 9 regulates iron mobilization at the blood-brain barrier in response to iron starvation. Mol Cell (2017) 29:2493–301. doi: 10.1017/ jbc.m116.769240

177. McCarthy RC, Kosman DJ. Glial Cell Ceruloplasmin and Hepcidin activity are required for brain microvascular endothelial cell iron efflux. J Biol Chem (2013) 288:17932–40. doi: 10.1074/jbc.M113.455428

178. Weston C, Kloubsicky J, Weston J, Connor J, Toms SA, Marko NF. Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas. PloS One (2016) 11: e0166591. doi: 10.1371/journal.pone.0166591

179. Legendre C, Garcia E. Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol Metab (2015) 26:322–31. doi: 10.1016/j.tem.2015.03.008

180. Tao L, Hecpicdin, an emerging and important player in brain iron homeostasis. J Trans Med (2018) 16:25. doi: 10.1186/s12976-018-1399-5

181. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell (2015) 28:441–55. doi: 10.1016/j.ccell.2015.09.002

182. Malecki EA, Devenyi AG, Beard JL, Connor JR. Existing and emerging Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 619300

183. McNulty W, Matuszak R, Devenyi AG, Beard JL, Connor JR. Existing and emerging Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 619300
specific. *Free Radic Biol Med* (2014) 74:200–9. doi: 10.1016/j.freeradbiomed.2014.06.022

245. Bodeker KL, Allen BG, Smith MC, Monga V, Sandhu S, Hohl RJ, et al. First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. *Clin Cancer Res* (2019) 25:6590–7. doi: 10.1158/1078-0432.CCR-19-0594

246. Baillie N, Carr AC, Peng S. The use of intravenous vitamin C as a supportive therapy for a patient with glioblastoma multiforme. *Antioxidants* (2018) 7. doi: 10.3390/antiox7090115

247. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. *N Engl J Med* (2005) 352:997–1003. doi: 10.1056/NEJMoa043331

248. Pegg AE, Dolan ME, Moschel RC. Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase. *Prog Nucleic Acid Res Mol Biol* (1995) 51:167–223. doi: 10.1016/S0079-6603(08)60879-X

249. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med* (2000) 343:1350–4. doi: 10.1056/NEJM200011093431901

250. Huang L, Boling W, Zhang J. Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme. *Med Gas Res* (2018) 8:24–8. doi: 10.4103/2045-9912.229600

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Crake, Burgess, Royds, Phillips, Vissers and Dachs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.